Community Research and Development Information Service - CORDIS

H2020

NanoSil4Cancer Report Summary

Project ID: 736632

Periodic Reporting for period 1 - NanoSil4Cancer (Smart Multifunctional silica-based Nanoparticles for Targeted Therapy)

Reporting period: 2016-09-01 to 2017-02-28

Summary of the context and overall objectives of the project

Anticancer drugs are administered at high doses, killing the diseased cells, but also showing severe toxic effects on the healthy ones. Unsustainable side effects and lack of therapeutic efficacy lead to patients non-adherence to the therapy and high medical costs.
NanoSil4Cancer is an innovative biocompatible device able to administer cancer therapies with low drug doses, high therapeutic efficacy and reduced side effects. Therapeutic efficacy increases because drugs are directly administered to cancer cells. NanoSiliCal reformulates known, approved drugs, through its proprietary drug delivery technology and creates new medications with improved clinical and economic benefits for patients and healthcare stakeholders.

The objectives for the Phase I study included (1) the analysis of customer needs, (2) analysis of the market size, (3) partner search and B2B strategy development, (4) the refinement of the business model and go-to-market strategy, (5) risk assessment, (6) elaboration of a long term perspective financial plan.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

NanoSiliCal conducted interviews with experts from the field and complemented the information with internet and database searches.
The epidemiological analysis provides evidence of the growth of cancer incidence and the need of treatments of higher efficacy and safety.
The economic impact of NanoSiliCal MSN prototypes development, analyzed on the base of financial projections, shows a highly competitive formulation development cost structure.
Several other drugs presenting features compatible with MSN have been identified, for developing NanoSilical pipeline.
Industrial stakeholders helped NanoSilical to define the company strategic plan to obtain marketing authorization and market penetration.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Based on the results of the phase I project, NanoSiliCal decided to develop two prototypes of nanoparticles loaded with two different drugs. NanoSiliCal planned to pursue completion of the clinical trial for one of the two prototypes, while progressing with the preclinical study for the other.

After the clinical trial stage, two different possible scenarios are foreseen, depending on the business agreement with present and possible future investors/partners : or the direct marketing of the product, or exclusive license of the prototype to a pharmaceutical company.
NanoSil4Cancer addresses cancer patient needs, developing an innovative technology for targeted drug delivery systems that can reduce side effects, thus increasing patients quality of life.

Related information

Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top